Table 1 Baseline characteristics of the women and men with and without anemia
Women | ||||
Parameter | All (n = 276) | Anemia (A) = Hb < 120 g/L (n = 89) | Nonanemic (NA) (n = 187) | p-value (A vs. NA) |
100% | 32.2% | 67.8% | ||
Age (years) mean ± SD | 85.9 ± 6.6 | 87.1 ± 6.0 | 85.4 ± 6.8 | 0.037 |
Hb (g/L) mean ± SD | 124.5 ± 13.6 | 109.0 ± 7.5 | 131.8 ± 8.7 | <0.001 |
Weight (kg) mean ± SD | 63.9 ± 14.0 | 62.0 ± 13.7 | 64.7 ± 14.1 | 0.137 |
Height (cm) mean ± SD | 159.6 ± 6.8 | 159.0 ± 6.5 | 159.8 ± 6.9 | 0.370 |
BMI (kg/m2) mean ± SD | 25.0 ± 5.0 | 24.6 ± 5.2 | 25.3 ± 5.0 | 0.296 |
Physical activity (h/week) mean ± SD | 0.51 ± 0.76 | 0.43 ± 0.69 | 0.54 ± 0.79 | 0.246 |
Social activity (h/week) mean ± SD | 1.97 ± 2.32 | 1.97 ± 2,28 | 1.97 ± 2,34 | 0.983 |
Medications in total ± SD | 6.8 ± 3.0 | 7.0 ± 3,3 | 6.7 ± 2,9 | 0.442 |
Warfarin | 7.2% (n = 20) | 3.4% (n = 3) | 9.1% (n = 17) | 0.087 |
ASA | 50.7% (n = 140) | 46.1% (n = 41) | 52.9% (n = 99) | 0.286 |
SSRI | 35.1% (n = 97) | 39.3% (n = 35) | 33.2% (n = 62) | 0.316 |
NSAID | 1.8% (n = 5) | 1.1% (n = 1) | 2.1% (n = 4) | 0.554 |
BNP > 100 ng/L (n = 273) | 50.5% | 55.7% | 48.1% | 0.242 |
eGFR < 60 mL/min (n = 273) | 61,9% | 67.4% | 59.2% | 0.192 |
eGFR < 30 mL/min (n = 273) | 7.0% | 11.2% | 4.9% | 0.053 |
Transthyretin < 0.23 g/L (n = 272) | 59.9% | 68.5% | 55.7% | 0.043 |
CRP ≥ 10 mg/L (n = 275) | 31.6% | 46.6% | 24.6% | <0.001 |
Ferritin > 204 μg/L (n = 276) | 17.8% | 25.8% | 13.9% | 0.015 |
Transferrin < 1.9 g/L (n = 275) | 4.7% | 6.8% | 3.7% | 0.262 |
Men | ||||
Parameter | All (n = 114) | Anemia (A) = Hb < 130 g/l (n = 59) | Nonanemic (NA) (n = 55) | p-value (A vs NA) |
100% | 51.8% | 48.2% | ||
Age (years) mean ± SD | 83.0 ± 6.7 | 84.2 ± 6.3 | 81.8 ± 7.0 | 0.064 |
Hb (g/L) mean ± SD | 128.6 ± 15.4 | 117.1 ± 9.0 | 140.9 ± 10.6 | <0.001 |
Weight (kg) mean ± SD | 73.9 ± 13.1 | 71.9 ± 11.9 | 76.0 ± 14.0 | 0.095 |
Height (cm) mean ± SD | 173 ± 6.7 | 172.4 ± 6.6 | 172.7 ± 6.9 | 0.811 |
BMI (kg/m2) mean ± SD | 24.8 ± 4.3 | 24.2 ± 4.1 | 25.4 ± 4.3 | 0.129 |
Physical activity (h/week) mean ± SD (n = 109) | 0.58 ± 0.94 | 0.39 ± 0.71 | 0.78 ± 1.11 | 0.030 |
Social activity (h/week) mean ± SD (n = 109) | 1.19 ± 1.94 | 1.04 ± 1.98 | 1.35 ± 1.89 | 0.401 |
Medications in total | 7.1 ± 3.2 | 7.6 ± 3,3 | 6.6 ± 3,0 | 0.078 |
Warfarin | 11.3% (n = 13) | 11.7% (n = 7) | 10.9% (n = 6) | 0.873 |
ASA | 56.1% (n = 64) | 52.5% (n = 31) | 60.0% (n = 33) | 0.423 |
SSRI | 33.3% (n = 38) | 30.5% (n = 18) | 36.4% (n = 20) | 0.508 |
NSAID | 0.9% (n = 1) | 1.7% (n = 1) | 0.0% (n = 0) | 0.332 |
BNP > 100 ng/L (n = 113) | 49.6% | 63.8% | 34.5% | 0.002 |
eGFR < 60 mL/min (n = 114) | 61.4% | 67.9% | 54.5% | 0.146 |
eGFR < 30 mL/min (n = 114) | 11.4% | 20.3% | 1.8% | 0.002 |
Transthyretin < 0.23 g/L (n = 114) | 56.1% | 62.7% | 49.1% | 0.143 |
CRP ≥ 10 mg/L (n = 112) | 34.8% | 45.8% | 22.6% | 0.010 |
Ferritin > 275 μg/L (n = 113) | 15.0% | 16.9% | 13.0% | 0.554 |
Transferrin < 1.9 g/L (n = 113) | 3.5% | 3.4% | 3.7% | 0.928 |